A graphic prediction tool may accurately estimate the chance of survival over two years in people ANCA-associated vasculitis (AAV), according to a study at a single Chinese hospital. The tool, a nomogram based on 16 predictive factors, was able to differentiate patients who survived from those who didn’t with…
News
The likelihood of disease recurrence in people with anti-neutrophilic cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) varies by disease type, with those with granulomatosis with polyangiitis (GPA) more likely to see their disease come back following successful treatment than people with microscopic polyangiitis (MPA), a study found. Patients with MPA may be…
Plasma exchange added to standard immunosuppressive treatments helps improve early kidney function in people with ANCA-associated vasculitis (AAV) who have glomerulonephritis, an inflammation of the kidneys’ filtering units, reducing the risk of kidney failure within the first year. That’s according to a new analysis of data from the…
Intravenous immunoglobulin (IVIg) therapy can reduce relapses and lessen long-term disability in people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare form of ANCA-associated vasculitis (AAV), a study from Italy has found. At patients’ one-year follow-up after IVIg treatment, reductions in peripheral neuropathy — damage to nerves outside…
Physicians typically do not overestimate the overall health of people with ANCA-associated vasculitis (AAV), a study of global assessments made by patients and their doctors in Australia reports. In cases where ratings between these two groups markedly differed, doctors tended to assign a lower score than did the people…
Lixudebart (ALE.F02), an experimental therapy Alentis Therapeutics is developing to help preserve kidney health in ANCA-associated vasculitis (AAV), showed a favorable safety profile in a Phase 2 clinical trial, the company has announced. A separate study testing lixudebart in people with liver disease also showed a good safety…
Adicet Bio has pushed to the second half of 2025 the expected timing for enrolling patients with ANCA-associated vasculitis (AAV) in an ongoing Phase 1 clinical trial testing ADI-001, an experimental CAR T-cell therapy for a number of autoimmune diseases. The company had said it expected enrollment…
Most children with ANCA-associated vasculitis (AAV) and kidney involvement at diagnosis will exhibit inactive kidney disease after one year, and more than two in five will show evidence of permanent kidney damage, according to data from an international registry study. A glomerular filtration rate (eGFR) — a standard measure…
More than half of the people living with ANCA-associated vasculitis (AAV) have infections caused by bacteria, fungi, or viruses, often in the respiratory tract, with more than one-third developing severe infections. That’s according to a meta-analysis of published data, which also identified several risk factors for infections in this…
A reduced glucocorticoid dosing regimen for inducing disease remission in people with ANCA-associated vasculitis (AAV) may be associated with a higher risk of poor disease outcomes in those with severe disease, compared with the standard-dose regimen. That’s according to a real-world study in France and Luxembourg that involved people…
Recent Posts
- Preparing for surgery with ANCA vasculitis is a team effort
- Serious heart disease seen early in newly diagnosed EGPA patients
- Gamma delta CAR T-cells are being tested to ‘reset’ AAV immune system
- Finding a little light on dark winter days is key with ANCA vasculitis
- Real-world data show high AAV remission rates with Tavneos